Drugs / chlorine dioxide
chlorine dioxide
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT01341041 | Aug 2004 → Dec 2007 | — | Rhode Island Hospital | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT04409873 | Mar 2021 → Sep 2022 | COVID-19, disorder of pharynx | University of California, San Francisco | Terminated | Missed primary Stop: Enrollment |
| Phase 2 | NCT03602066 | Feb 2019 → Nov 2022 | head and neck carcinoma | University of Arizona | Terminated | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02113137 | Sep → Oct 2013 | — | Ei Ei Aung | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00867035 | Mar 2008 → Mar 2009 | — | University of California, San Francisco | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT03160560 Comparator | Aug → Nov 2016 | mouth disorder | Rowpar Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Chlorine Dioxide | “Over the counter: CloSYS Ultra Sensitive Rinse (Rowpar Pharmaceutical Inc., USA) contains stabilized chlorine dioxide (ClO2)” NCT04409873 ↗5“CloSYS Oral Rinse product containing 0.1% stabilized chlorine dioxide (sodium chlorite) in aqueous solution.” NCT03160560 ↗ |
| Known as | CACD | “This research is being done because the investigators are trying to examine the safety and effectiveness of this wound cleaning liquid, CACD (chlorine dioxide).” NCT01341041 ↗ |
| Known as | Chlorine peroxide | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297725 ↗ |
| Route | Oral | “Given via oral rinse” NCT03602066 ↗ |